These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 32300166)

  • 1. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.
    Régnier M; Polizzi A; Smati S; Lukowicz C; Fougerat A; Lippi Y; Fouché E; Lasserre F; Naylies C; Bétoulières C; Barquissau V; Mouisel E; Bertrand-Michel J; Batut A; Saati TA; Canlet C; Tremblay-Franco M; Ellero-Simatos S; Langin D; Postic C; Wahli W; Loiseau N; Guillou H; Montagner A
    Sci Rep; 2020 Apr; 10(1):6489. PubMed ID: 32300166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα.
    Liang N; Damdimopoulos A; Goñi S; Huang Z; Vedin LL; Jakobsson T; Giudici M; Ahmed O; Pedrelli M; Barilla S; Alzaid F; Mendoza A; Schröder T; Kuiper R; Parini P; Hollenberg A; Lefebvre P; Francque S; Van Gaal L; Staels B; Venteclef N; Treuter E; Fan R
    Nat Commun; 2019 Apr; 10(1):1684. PubMed ID: 30975991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity.
    Stec DE; Gordon DM; Hipp JA; Hong S; Mitchell ZL; Franco NR; Robison JW; Anderson CD; Stec DF; Hinds TD
    Am J Physiol Regul Integr Comp Physiol; 2019 Nov; 317(5):R733-R745. PubMed ID: 31483154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
    Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
    J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-fat diet induces fibrosis in mice lacking CYP2A5 and PPARα: a new model for steatohepatitis-associated fibrosis.
    Chen X; Acquaah-Mensah GK; Denning KL; Peterson JM; Wang K; Denvir J; Hong F; Cederbaum AI; Lu Y
    Am J Physiol Gastrointest Liver Physiol; 2020 Nov; 319(5):G626-G635. PubMed ID: 32877213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway.
    Xie Y; Jin Y; Wen J; Li G; Huai X; Duan Y; Ni F; Fu J; Li M; Li L; Yan M; Cao L; Xiao W; Yang H; Wang ZZ
    Biomed Pharmacother; 2024 Jul; 176():116908. PubMed ID: 38850668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARα.
    Zhou W; Du Z
    J Sci Food Agric; 2024 Nov; 104(14):8634-8645. PubMed ID: 38952322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
    Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
    Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fat mass and obesity-associated protein promotes liver steatosis by targeting PPARα.
    Wei X; Zhang J; Tang M; Wang X; Fan N; Peng Y
    Lipids Health Dis; 2022 Mar; 21(1):29. PubMed ID: 35282837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
    Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
    Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression.
    Loyer X; Paradis V; Hénique C; Vion AC; Colnot N; Guerin CL; Devue C; On S; Scetbun J; Romain M; Paul JL; Rothenberg ME; Marcellin P; Durand F; Bedossa P; Prip-Buus C; Baugé E; Staels B; Boulanger CM; Tedgui A; Rautou PE
    Gut; 2016 Nov; 65(11):1882-1894. PubMed ID: 26338827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal peroxisome proliferator-activated receptor α-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis.
    Yan T; Luo Y; Yan N; Hamada K; Zhao N; Xia Y; Wang P; Zhao C; Qi D; Yang S; Sun L; Cai J; Wang Q; Jiang C; Gavrilova O; Krausz KW; Patel DP; Yu X; Wu X; Hao H; Liu W; Qu A; Gonzalez FJ
    Hepatology; 2023 Jan; 77(1):239-255. PubMed ID: 35460276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.